^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
05/04/2023
Excerpt:
Pancreatic Adenocarcinoma….PRINCIPLES OF SYSTEMIC THERAPY….Other Recommended Regimens... Nivolumab + ipilimumab (if TMB-H [≥10 mut/Mb]) (category 2B)
